Clinical Research Directory

* Inclusion Criteria: 1. Subjects voluntary agreement to provide written informed consent. 2. Aged 18 to 70 years, either sex. 3. Clinical laboratory values meet screening criteria. 4. Positive test for CD19 and/ or BCMA SLE: * Meets at least 1 classification criteria≥6 months for SLE. * At screening, antinuclear antibody, and/or anti-dsDNA antibody, and/or anti-Smith antibody should be positive. * Fulfill relapsed/refractory SLE conditions. AAV: * Meets the 2022 ACR/EULAR classification criteria for AAV. * Positive test for anti-MPO or p-ANCA or anti-PR3 or anti-MPO antibodies at screening. * Fulfill relapsed/refractory AAV conditions. SSc: * Meets the 2013 ACR/EULAR classification criteria for SSc. * At screening, mRSS is higher than 10. * Fulfill relapsed/refractory SSc conditions. IIM: * Meets 2017 EULAR/ACR classification criteria for IIM. * Positive test for myositis-associated antibodies or myositis-specific antibodies at screening. * Fulfill relapsed/refractory IIM conditions. SjS： * Meets the 2016 ACR/EULAR diagnostic criteria for SjS. * Positive test for anti-SSA and/or anti-SSB antibodies at screening. * Fulfill relapsed/refractory SjS conditions. Exclusion Criteria: 1. Active infections such as hepatitis and tuberculosis. 2. Other autoimmune diseases. 3. Serious underlying diseases such as tumor, uncontrolled diabetes. 4. Female subjects who were pregnant, breastfeeding. 5. Those with a history of major organ transplantation. 6. Have received autologous cell therapy of any target before.